Benzinga
Benzinga
Benzinga
lundi, septembre 14

Acurx Pharmaceuticals Inc

ACXPNASDAQ
Trade with Public
Trade with Public
$1.39
-0.01-0.71%
À la clôture: Sep 14, 5:00 PM EST
$1.39
N/A
Après les heures: 8:05 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerRapport sur les stocks

Acurx Pharmaceuticals Financials

Acurx Pharmaceuticals (ACXP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per
Benzinga Newsdesk

What's Going On With Acurx Pharmaceuticals Stock Today?

Acurx Pharmaceuticals (NASDAQ:ACXP) shares down on Friday after reporting net loss for Q4 2025, but with positive cash and $1.5M raised.
Nabaparna Bhattacharya

Earnings Scheduled For March 13, 2026

Benzinga Insights

PRO
Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.65) by 55.62 percent. This is a 78.53 percent increase over losses of $(3.40) per share
Benzinga Newsdesk

PRO
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.31) by 6.11 percent. This is a 64.35 percent increase over losses of $(3.45) per share
Benzinga Newsdesk

Earnings Scheduled For November 12, 2025

Benzinga Insights

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved